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Pain control for uterine fibroid embolisation-an initial
experience in East Africa
G. Mwaka, V. Mung’ayi, N. Hacking and W. Stones
SUMMARY
Uterine fibroid embolisation (UFE) generates moderate to severe post-procedural pain.
We present a case series of 24 patients who underwent UFE during our first experience
in managing the sometimes excruciating pain that accompanies embolisation of the
uterine arteries. We also show the evolution of our protocol for post-procedural pain
management from a first to second round of procedures.
INTRODUCTION
Uterine fibroid embolisation is a well established
effective method for treating symptomatic uterine
fibroids (1-4) but is new in African clinical practice.
It is suggested that UFE causes degeneration and
shrinkage of fibroids, controlling or substantially
improving menorrhagia, pelvic pain and pressure
in more than 80% of patients. The magnetic
resonance imaging (MRI) and pathologic findings
reported suggest that the fibroids undergo
infarction and subsequent hyaline degeneration
(5-7). The infarction of the fibroids occurs in the
first hours after embolisation (8), causing severe
ischaemic pain in many patients. This makes timely
and adequate pain management a key point in the
success of UFE. In some centres, pain management
for UFE is supervised by the interventional
radiologist while in others this is managed by
anaesthesiologists.
We report our experience from the first series
of UFE procedures in East Africa undertaken at the
Aga Khan University Hospital, Nairobi. A visiting
interventional radiologist, who runs a busy UFE
service in the United Kingdom and Trinidad and
Tobago, requested a standby anaesthesiologist in
case a need arose for pain control.
He had observed that in Trinidad and Tobago
where anaesthesiologists took care of the postprocedural pain management, pain control was

better than in the centres where he performed the
UFE and simultaneously supervised the sedation
and pain management for the patients.
	Two UFE workshops, both conducted over
a three day period, in December 2009 and April
2010. A protocol for sedation and pain control
developed by the interventional radiologist was
recommended in the first workshop. It had to be
modified after three UFE procedures as a result
of patient response, observation and feedback to
the medications administered. The modifications
were done with an endpoint of achieving optimised
post-procedure pain control.
	For the second workshop we applied the
protocol that had been used on the last day of
the first workshop. We report this series of UFE
procedures to document our experience and provide
new insights on ways of managing the sometimes
excruciating pain that follows embolisation.
Case series presentation
During these two workshops we cared for 24
patients undergoing UFE, 12 in each. The first round
was the most challenging since it was our initial
experience in UFE management at the Aga Khan
University Hospital. All patients were admitted on
the day of the procedure and reviewed the same
day. Characteristics of the women who underwent
the procedure are shown in Table 1.
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Table 1
Baseline variables of women undergoing UFE
Age (years)		2009 (n=12)
18-30
1
31-35
1
36-45
7
Above 45
3
Parity
Nulliparous
9
1
2
2
1
3
0
CASE ONE
On the first day, the protocol for pain management
used had been recommended by the interventional
radiologist. Three patients underwent UFE and received
midazolam 4mg and Augmentin 1.2gm intravenously
(iv) prior to local anaesthesia being infiltrated over
the femoral region. They were then given diclofenac
suppository 100mg, intravenous paracetamol 1gm

%
2010 (n=12)
8.3		 1			
8.3		 0			
58.3		 10			
25		 1			
75		
16.6		
8.3		
0		

8			
3			
0			
1			

%
8.3
0
83.3
8.3
66.6
25
0
8.3

before and at the start of the procedure. Morphine 5mgs
was then injected intravenously before each artery was
embolised followed by intravenous Buscopan 10mg.
Thereafter, pain control medication was administered
as per the protocol shown in table 2. The three patients
undergoing UFE on day one had moderate to severe
post procedural pain. This observation made us modify
our pain management protocol to the one shown in
Table 2.

Table 2
Initial algorithm for pain control during UFE
Patient admission	IV access
	IV midazolam 4 mg
Angiography suite
Pulse oximeter monitoring
	Morphine 5 mg before embolization
of each uterine artery.
	Diclofenac suppository 100mg
	IV paracetamol 1 gm
	IV buscopan 10 mg 8 hourly
Recovery room
PCA* morphine 1mg/ml
+/- morphine bolus 2-4 mg
	Nausea- IV ondansetron 4mg
	Discharge to ward after pain
stabilisation.
Re-admission to ward	Morphine PCA
	Oral Diclofenac/paracetamol to
continue.
	IV ondansetron 4mg PRN#
	IV Metoclopramide 10 mg PRN
Next morning 	Removal of IV drip, PCA
	Continue oral diclofenac
	Betapyn 2 tablets 8 hourly
Patient discharge 	Diclofenac 50 mg 6 hourly
*PCA-patient controlled analgesia
#PRN- As required
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Table 3
Revised algorithm for pain control during UFE
Patient admission	IV access
Recovery room
PCA instructions and connection
Pulse oximeter monitoring
	Morphine 2 mg bolus, then 2mg/5-7
minutes
	IV paracetamol 1 gm
	IV buscopan 10 mg 8 hourly
Angiography suite
Pulse oximeter monitoring
	Morphine infusion 2-4 mg/hour
	IM Diclofenac 75 mg
	IV paracetamol 1 gm
Recovery room	Morphine PCA and infusion to continue
	Nausea- IV ondansetron 4mg
	Discharge to ward after pain stabilisation
Re-admission to ward	Morphine PCA and infusion overnight
	Oral Diclofenac/paracetamol to continue
	IV ondansetron 4mg PRN#
	IV Metoclopramide 10 mg PRN
Next morning	Removal of IV drip, PCA
	Continue oral diclofenac
	Betapyn 2 tablets 8 hourly
Patient discharge 	Diclofenac 50 mg 6 hourly
	Betapyn 2 tablets 8 hourly
Betapyn TM is a mixture of codeine 10 mg and paracetamol 300mg
Day two began with a post-procedural follow up
and review of patients who had undergone UFE the
previous day. Thereafter, the protocol was adjusted
during the pre- and peri-procedural period as
follows:
• 	Intravenous access, intravenous paracetamol
being infused before preparation and draping
plus 2mg of midazolam
• 	Nasal prongs and oxygen flow at 3Litres/
minute
• 	Morphine given as the previous day.
• 	Intramuscular (im) diclofenac used (instead of
suppository)
• 	Commenced iv morphine infusion at 2-4mg/
hour on completion of procedure.
	On day three, we continued with post-procedural
follow up and review of patients. Only one patient
who had had the procedure on the first day was still
an inpatient owing to moderate pain of 4/10 on the
Visual Analogue Scale (VAS). We completely changed
the protocol to the one depicted in Table 3.
	This group had better pain control than the
previous days. On day four, we continued with the
post-procedural follow up of day three patients. All

patients were discharged. Thus at the end of the
first workshop, three out of twelve patients were
discharged with pain score of 0/10 and the rest were
discharged with mild pain (VAS score 1-3).
CASE TWO
This workshop was held in April 2010, we used the
protocol in table 3 for the pain management of all
patients. This time the anaesthesiologist was involved
in the pre-procedural assessment of the patients as
there was ample time for preparation and scheduling
of the patients. All patients were seen before the
procedure and instructed on the use of PCA.
On the first day, four patients underwent UFE.
One patient had itching as a side effect and another
had nausea and vomiting. All four patients had no
pain to mild pain and were discharged the next
day.
	On the second day we began with review of the
post-procedural patients of day one. The patient who
had vomited the previous day had recovered. We
continued to use the same protocol with no problems.
After UFE, one of the five patients developed urinary
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retention that was treated with bladder catheterisation
for 24 hours. She was agitated and complaining
of severe pain but once the morphine had been
reduced she reported not remembering the severe
pain. However she had mild pain at that time. She
spent three days in hospital. The final three patients
reported no pain to mild pain as complaints. They
were discharged the day following the procedure
with no other complaints.
	This service evaluation and improvement study
was approved by the Aga Khan University, East
Africa, Research and Ethics committee.
Discussion
Uterine fibroid embolisation is an effective treatment
for uterine fibroids (9). However, this procedure
is associated with a high incidence of moderate
to severe pain and post-operative nausea and
vomiting (PONV) (10). UFE is a procedure which is
normally performed in radiology suites without an
anaesthesiologist getting involved in the patient’s
management (11).On this basis we were asked to
be on standby owing to the fact the patients would
be sedated using the interventional radiologists’
protocol. Due to the immediate intense pain
generated by the infarcting fibroids we progressively
(5-7,10) altered the protocol suggested by the
interventional radiologist during the first project
to that shown in Table 3.
	The protocol in Table 3 provides the
anaesthesiologist a much better opportunity to get
involved in pain management as early as possible and
gives a sequential approach to the entire management
of the whole UFE procedure. With the model
described in Table 1, where the need for evolution
to the model shown in Table 2 arose, it will be noted
that the first encounter between the anaesthesiologist
and the patient was in the recovery room with this
development, (Table 2) patients were seen by the
anaesthesiologist the day before or at admission on
the day of the procedure. In other institutions the
patients are also referred to an Acute Pain Service for
evaluation by an anaesthesiologist and instructed on
the use of patient-controlled analgesia (12).
	This early referral to an Acute Pain Service and
involvement of the anaesthesiologist greatly improves
outcome through increased knowledge among
patients of the use of the PCA and post-procedural
pain control. Morphine in PCA has been used by
many investigators for management of post-UFE
pain (2,13,14). During the first round of procedures
we noted that a concentration of morphine 1mg/ml
in a PCA device was not an adequate dose for the
patients who kept using it a lot.Half the volume with
a concentration of 2mg/ml was therefore used during
the second round of treatments. Patients used the
PCA less during this round probably due to the fact
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that we had given a significant amount during the
procedure and they were transferred to the ward with
an infusion of morphine running. We encountered
more problems with morphine during the second
round of treatments mainly nausea/vomiting and
urine retention. We suspect that these adverse effects
could be avoided with the use of epidural analgesia
using local anaesthetic and low dose opioid (14).
However this might prolong hospital admission by
an extra day and would necessitate the development
of another protocol using epidural analgesia with
boluses or infusion of local anaesthetics with or
without opioid additives. Costs of the procedure
are an important constraint in this setting and an
appropriate strategy is to minimize the cost of agents
and devices used while facilitating the rapid recovery
to keep the inpatient stay as short as possible. We
discharged our patients with the analgesics shown in
table 3 and none required additional pain control in
hospital except for the first patient in the first project
who had moderate to severe pain.
	This intractable pain was later noted to have been
due to a persisting intrauterine (submucosal) fibroid
that required hysteroscopic resection.Patients were
given direct telephone access to the anaesthesiologist
following discharge, which enabled rapid provision
of advice and reassurance. This access was greatly
appreciated by the patients.
In conclusions, pain is and will always be a common
side effect of UFE. There is currently no consensus
regarding the best method for managing pain in
UFE patients (15). This being a new experience of
managing UFE patients in Kenya and probably in the
East African region it would be prudent to further
investigate and produce other protocols including
one involving epidural analgesia. This will be feasible
when the participating departments of gynaecology,
anaesthesiology and radiology work closely together
so that patients can be educated in use of the PCA and
other modalities of analgesia as well as optimizing
them for the procedure.
Pre-procedural block of the superior hypogastric
nerve via the anterior transabdominal approach has
been advocated by some and has allowed UFE to
be performed as a day case procedure (16). It is also
thought that with adequate analgesia, the procedure
maybe performed without sedation (17).
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